RODNEY GILSTRAP, District Judge.
Defendant Supercell OY ("Supercell") previously filed two Motions to Dismiss. (Dkt. Nos. 17 & 97.)
After reviewing the briefing for the Motions to Dismiss, the Report and Recommendation, and Supercell's Objections, the Court agrees with the reasoning provided within the Report and Recommendation. The Court also notes that, while Supercell argues that claim 1 of the '137 Patent, claim 8 of the '481 Patent, claim 1 of the '873 Patent, and claim 8 of the '655 Patent are representative of the other asserted claims, Supercell has failed to show that these claims are representative of the other asserted claims for the purposes of subject matter eligibility. While Plaintiff GREE, Inc. ("GREE") states within its complaint that these listed claims are representative of the patent-in-suit, those statements were made within GREE's discussion of infringement. (See Dkt. No. 1 at ¶¶ 40, 55, 72, & 85.) GREE's statements within the complaint should not be construed as admissions that the aforementioned claims are representative of the other asserted claims within the patent-in-suit for the purposes of resolving issues on subject matter eligibility. While Supercell's Motion includes further argument as to why the other claims of the patent-in-suit are ineligible, these arguments fail to show that the aforementioned claims are representative of the other claims.
A statement that a claim is representative for purposes of infringement—without more— is insufficient to show that a claim is representative for purposes of invalidity under 35 U.S.C. § 101. GREE, Inc. v. Supercell Oy, Case No. 2:19-CV-00161-JRG-RSP, 2020 WL 475443, at *1 (E.D. Tex. Jan. 29, 2020). This is because the representativeness inquiry with respect to infringement is completely different than the inquiry with respect to validity under 35 U.S.C. § 101. An infringement analysis compares the asserted claims to an accused product or method and focuses on each limitation of the asserted claims. See, e.g., Adams Respiratory Therapeutics, Inc. v. Perrigo Co., 616 F.3d 1283, 1287-88 (Fed. Cir. 2010) ("As we have repeatedly said, it is error for a court to compare in its infringement analysis the accused product or process with the patentee's commercial embodiment or other version of the product or process;
In contrast to infringement, a determination related to patent-eligible subject matter requires an entirely different analysis. For example, to determine eligibility, the Court must examine whether the claims capture an "inventive concept" and must compare that inventive concept to the universe of prior art to determine whether the claims merely involve activity that was "well-understood, routine and conventional" from the perspective of "a skilled artisan in the relevant field" at the time of patenting. PPS Data, LLC v. Jack Henry & Assocs., Inc., 404 F.Supp.3d 1021, 1040 (quoting Berkheimer v. HP Inc., 881 F.3d 1360, 1368 (Fed. Cir. 2018), cert. denied, No. 18-415, 2020 WL 129532 (U.S. Jan. 13, 2020)). Because the eligibility comparison is between the claims and the prior art, rather than the claims and an accused product, the representativeness analysis for infringement does not automatically overlap with the representativeness analysis for eligibility.
Thus, in addition to the reasons provided within the Report and Recommendation, the Court concludes that Supercell's Motion should also be denied because it fails to show that claim 1 of the '137 Patent, claim 8 of the '481 Patent, claim 1 of the '873 Patent, and claim 8 of the '655 Patent are representative of the other asserted claims within the patents-in-suit. Consequently, the Court